Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 161 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adult Attention Deficit Hyperactivity Disorder Clear all
Completed Phase 4 Interventional Results available

An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.

NCT01873729
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT02699086
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
PDC-1421 Capsule
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Investigating the Effect of Vortioxetine in Adult ADHD Patients

NCT02327013
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Beverly Hills, California • Garden Grove, California • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?

NCT01127607
View directory record Official record
Conditions
ADHD
Interventions
lisdexamfetamine
Drug
Lead sponsor
Florida International University
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

NCT05972044
View directory record Official record
Conditions
ADHD
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Encino, California • Garden Grove, California • Newport Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse

NCT00248092
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2007 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist

NCT01673594
View directory record Official record
Conditions
ADHD, Stimulant-Induced Euphoria
Interventions
SODAS MPH, Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

NCT01399827
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions
ADHD Medication, Omega-3 Fatty Acids
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

NCT01939353
View directory record Official record
Conditions
Adult ADHD
Interventions
CTN SR, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults

NCT02127931
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Groundskeeper for ADHD group, Groundskeeper for control group
Device
Lead sponsor
CogCubed, Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

NCT02604407
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jun 7, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Mindfulness Intervention for College Students With ADHD

NCT06076967
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mindfulness Awareness Practices for ADHD (adapted), Services-As-Usual
Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
17 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tuscaloosa, Alabama • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS

NCT00586573
View directory record Official record
Conditions
ADHD
Interventions
memantine hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Jun 7, 2026, 2:12 PM EDT
Completed No phase listed Observational

Autism Spectrum Disorders (ASD) Driving Study

NCT01263756
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The Reinforcing Mechanisms of Smoking in Adult ADHD

NCT00573859
View directory record Official record
Conditions
ADHD
Interventions
ADHD medication, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Early Phase 1 Interventional

Oxytocin and Cognitive Control in Adult ADHD

NCT03136263
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Oxytocin nasal spray, Placebo nasal spray
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NCT04839562
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Solriamfetol 75 MG, Solriamfetol 150 MG, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Nicotine and Behavior in Adult ADHD

NCT00573248
View directory record Official record
Conditions
ADHD
Interventions
Nicotine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 3 Interventional

Open-label Safety Study in Adults With ADHD

NCT02160262
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
65
States / cities
Beverly Hills, California • Encino, California • Escondido, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

NCT03834766
View directory record Official record
Conditions
ADHD
Interventions
AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Jun 7, 2026, 2:12 PM EDT
Recruiting Phase 4 Interventional

R61/33 - VR Study Phase 4

NCT07169760
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Meta Quest 3 VR Headset with noise cancelling headphones
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 25 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Baton Rouge, Louisiana • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults

NCT00278473
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Meta-Cognitive Therapy, Supportive Therapy
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jun 7, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

NCT01533493
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Interventions
Placebo, Memantine Hydrochloride, OROS-Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Jun 7, 2026, 2:12 PM EDT